| Name | apolipoprotein |
|---|---|
| Synonyms | APOA 2; APOA2; APOAL; APOARGC; Apolipoprotein; Apolipoprotein (A) related gene C; Apolipoprotein (a); Apolipoprotein A II… |
| Name | copper sulfate |
|---|---|
| CAS | sulfuric acid copper(2+) salt (1:1) |
| PubMed | Abstract | RScore(About this table) | |
|---|---|---|---|
| 12729008 | Arai H, Uchida K, Fukunaga K, Nagasaka Y, Mohri S, Furumoto H, Kuramitsu Y, Nakamura K: Effect of on the oxidative modification of apolipoprotein E in human very-low-density lipoprotein. Biosci Biotechnol Biochem. 2003 Feb;67(2):402-5. The oxidative modification of apolipoprotein (apo) E and lipid peroxidation in human very-low-density lipoprotein (VLDL) induced by and cupric ions in vitro were strongly suppressed by enrichment with (alpha-Toc; 170 microM). |
1(0,0,0,1) | Details |
| 11590223 | Edelstein C, Nakajima K, Pfaffinger D, Scanu AM: Oxidative events cause degradation of apoB-100 but not of apo [a] and facilitate enzymatic cleavage of both proteins. J Lipid Res. 2001 Oct;42(10):1664-70. Lipoprotein [a] (Lp [a]) contains equimolar amounts of apoB-100 and apolipoprotein [a] (apo [a]). |
1(0,0,0,1) | Details |
| 9554802 | Hayek T, Attias J, Smith J, Breslow JL, Keidar S: Antiatherosclerotic and antioxidative effects of captopril in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol. 1998 Apr;31(4):540-4. The effect of the angiotensin-converting enzyme (ACE) inhibitor, captopril, on the development of atherosclerosis was determined in the apolipoprotein (apo) E-deficient mice. |
1(0,0,0,1) | Details |
| 9166989 | Napoli C, Triggiani M, Palumbo G, Condorelli M, Chiariello M, Ambrosio G: Glycosylation enhances radical-induced modifications and decreases acetylhydrolase activity of human low density lipoprotein. Basic Res Cardiol. 1997 Apr;92(2):96-105. Oxidation of glc-LDL also induced a higher degree of apolipoprotein-B100 modifications than n-LDL, with increased electrophoresis mobility and decreased TNBS reactivity. |
1(0,0,0,1) | Details |
| 11200090 | Malminiemi K, Palomaki A, Malminiemi O: Comparison of LDL trap assay to other tests of antioxidant capacity; effect of and lovastatin treatment. Free Radic Res. 2000 Nov;33(5):581-93. TRAP correlated with the lag time (r = 0.55, p < 0.001) and alpha-TOH consumption time (r = 0.48, p < 0.05), and inversely with apolipoprotein Al (r = -0.51, p < 0.05). |
1(0,0,0,1) | Details |
| 9245700 | Keidar S, Attias J, Smith J, Breslow JL, Hayek T: The angiotensin-II receptor antagonist, losartan, inhibits LDL lipid peroxidation and atherosclerosis in apolipoprotein E-deficient mice. Biochem Biophys Res Commun. 1997 Jul 30;236(3):622-5. The potential antiatherogenic actions of the angiotensin II receptor antagonist, losartan were investigated in apolipoprotein (apo) E deficient mice, an animal model with severe hypercholesterolemia and extensive atherosclerosis. |
1(0,0,0,1) | Details |